NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Low, Intermediate, or High Dose Suramin in Treating Patients With Hormone-Refractory Prostate Cancer

Phase 3

Completed

Conditions: Prostate Cancer

Interventions: Drug: Suramin

First Posted Date: 2003-10-22

Last Posted Date: 2013-02-28

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 390

Registration Number: NCT00002723

Locations: 🇺🇸
CCOP - Geisinger Clinic and Medical Center, Danville, Pennsylvania, United States
🇺🇸
CCOP - Marshfield Medical Research and Education Foundation, Marshfield, Wisconsin, United States
🇺🇸
Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States

and more 24 locations

SU6668 in Treating Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: orantinib
Other: laboratory biomarker analysis
Other: pharmacological study

First Posted Date: 2003-10-21

Last Posted Date: 2013-01-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 12

Registration Number: NCT00024206

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Interferon Alfa Plus Thalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Phase 2

Terminated

Conditions: Recurrent Grade 1 Follicular Lymphoma
Recurrent Grade 2 Follicular Lymphoma

Interventions: Biological: recombinant interferon alfa
Drug: thalidomide
Other: laboratory biomarker analysis

First Posted Date: 2003-10-15

Last Posted Date: 2013-01-25

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 35

Registration Number: NCT00015912

Locations: 🇺🇸
University of Colorado, Denver, Colorado, United States

Thalidomide in Treating Patients With Recurrent or Persistent Endometrial Cancer

Phase 2

Completed

Conditions: Endometrial Adenoacanthoma
Endometrial Adenocarcinoma
Endometrial Adenosquamous Cell Carcinoma
Endometrial Clear Cell Carcinoma
Endometrial Papillary Serous Carcinoma
Recurrent Endometrial Carcinoma

Interventions: Drug: thalidomide
Other: laboratory biomarker analysis

First Posted Date: 2003-10-15

Last Posted Date: 2013-01-24

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 60

Registration Number: NCT00025467

Locations: 🇺🇸
Gynecologic Oncology Group, Philadelphia, Pennsylvania, United States

Gemcitabine Plus Flavopiridol in Treating Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: alvocidib
Drug: gemcitabine hydrochloride

First Posted Date: 2003-10-15

Last Posted Date: 2013-02-28

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 58

Registration Number: NCT00007917

Locations: 🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Surgery Plus Chemotherapy (Doxorubicin, Vincristine and Etoposide), Mitotane, and Tariquidar to Treat Adrenocortical Cancer

Phase 2

Completed

Conditions: Adrenal Cortex Neoplasms

Interventions: Drug: XR9576 (Tariquidar)

First Posted Date: 2003-10-10

Last Posted Date: 2012-09-18

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 50

Registration Number: NCT00071058

Locations: 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States

Ixabepilone in Treating Patients With Advanced Urinary Tract Cancer

Phase 2

Completed

Conditions: Distal Urethral Cancer
Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter
Proximal Urethral Cancer
Recurrent Bladder Cancer
Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter
Recurrent Urethral Cancer
Regional Transitional Cell Cancer of the Renal Pelvis and Ureter
Stage III Bladder Cancer
Stage IV Bladder Cancer
Transitional Cell Carcinoma of the Bladder

Interventions: Drug: ixabepilone

First Posted Date: 2003-10-09

Last Posted Date: 2013-01-24

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 45

Registration Number: NCT00021099

Locations: 🇺🇸
Eastern Cooperative Oncology Group, Boston, Massachusetts, United States

GTI-2040 and High-Dose Cytarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia

Phase 1

Completed

Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
Recurrent Adult Acute Myeloid Leukemia

Interventions: Biological: GTI-2040
Drug: cytarabine
Other: pharmacological study
Other: laboratory biomarker analysis

First Posted Date: 2003-10-07

Last Posted Date: 2013-06-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 51

Registration Number: NCT00070551

Locations: 🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States

Alvocidib in Treating Patients With Metastatic or Unresectable Refractory Solid Tumors or Hematologic Malignancies

Phase 1

Terminated

Conditions: Hematopoietic/Lymphoid Cancer
Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: alvocidib
Other: pharmacological study
Radiation: fludeoxyglucose F 18
Other: fluorine F 18 fluorothymidine
Procedure: positron emission tomography

First Posted Date: 2003-10-07

Last Posted Date: 2013-12-16

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 100

Registration Number: NCT00070239

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Rituximab, Prednisone, Cyclophosphamide, Doxorubicin, Vincristine, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Previously Untreated Mantle Cell Lymphoma

Phase 2

Completed

Conditions: Lymphoma

First Posted Date: 2003-10-07

Last Posted Date: 2014-01-28

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT00070447

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸
Hahnemann University Hospital, Philadelphia, Pennsylvania, United States
🇺🇸
CCOP - Columbus, Columbus, Ohio, United States

and more 84 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy